key: cord-0849604-p1716rib
authors: Manolis, Antonis S.; Manolis, Antonis A.; Manolis, Theodora A.; Apostolaki, Naomi E.; Melita, Helen
title: COVID-19 Infection and Body Weight: A Deleterious Liaison in a J-Curve Relationship
date: 2021-11-03
journal: Obes Res Clin Pract
DOI: 10.1016/j.orcp.2021.10.006
sha: 9f87df230bee0d53d0ceb72e4483ea60a33a9fcf
doc_id: 849604
cord_uid: p1716rib

During the course of the COVID-19 pandemic, obesity has been shown to be an independent risk factor for high morbidity and mortality. Obesity confers poor outcomes in younger (<60 years) patients, an age-group considered low-risk for complications, a privilege that is negated by obesity. Findings are consistent, the higher the body mass index (BMI) the worse the outcomes. Ectopic (visceral) obesity also promotes proinflammatory, prothrombotic, and vasoconstrictive states, thus enhancing the deleterious effects of COVID-19 disease. Less, albeit robust, evidence also exists for a higher risk of COVID-19 infection incurred with underweight. Thus, the relationship of COVID-19 and BMI has a J-curve pattern, where patients with both overweight/obesity and underweight are more susceptible to the ailments of COVID-19. The pathophysiology underlying this link is multifactorial, mostly relating to the inflammatory state characterizing obesity, the impaired immune response to infectious agents coupled with increased viral load, the overexpression in adipose tissue of the receptors and proteases for viral entry, an increased sympathetic activity, limited cardiorespiratory reserve, a prothrombotic milieu, and the associated comorbidities. All these issues are herein reviewed, the results of large studies and meta-analyses are tabulated and the pathogenetic mechanisms and the BMI relationship with COVID-19 are pictorially illustrated.

meta-analysis of 5 studies for patients with obesity and ARDS, supporting a possible "obesity paradox" (inverse association between BMI and mortality). 5 Indeed, another meta-analysis of 24 studies also provided evidence of an "obesity paradox" in a very large cohort of patients with ARDS (N=9,187,248); although obesity was associated with increased risk of ARDS, it conferred a lower risk of mortality in ARDS patients (pooled odds ratio-OR 0.63, P=0.04, I 2 =96%). 6 However, during the course of the COVID-19 pandemic, obesity has been shown to be an independent risk-factor for high mortality in a prospective UK study, in which the clinical features of >20,000 hospitalized patients with COVID-19 were analyzed. 7 Over the last several months, many other studies have demonstrated that COVID-19 patients with overweight and obesity have more severe disease, are at increased risk for intubation and have higher mortality compared to those with normal BMI. On the other hand, high frequency of obesity has been reported among COVID-19 patients admitted in intensive care units (ICUs); apparently, disease severity increases with BMI. 8 Interestingly, a recent analysis of differences in factors influencing COVID-19-related mortality among various countries showed that in addition to low socio-economic status as reflected by the gross domestic product (GDP), obesity was the second-best predictor of death with a correlation coefficient (R) value of 0.43 vs an Rvalue of 0.65 for GDP. 9 Finally, a large multicenter observational cohort study (N=35,506) indicated that the "obesity paradox" is not present in critically ill (ICU) patients with COVID-19-related respiratory failure. 10 

The main large individual studies reporting on the association between obesity and COVID-19 outcomes in >1000 participants are displayed in Table 1 . A population study in England (N=334,329; age 56.4±8.1 years; 54.5% women), where ~0.2% (n=640) were hospitalized for COVID-19, indicated that there was a linear trend in the likelihood of COVID-19 hospitalization with increasing BMI, that was evident in the overweight (odds ratio-OR 1.39) and obese stage I (OR 1.70) and stage II (OR 3.38) compared to normal weight. 11 Another multicenter retrospective cohort study enrolling 1,461 patients (median age 64 years; 73% males; median BMI 28.1 kg/m 2 ) showed a significant linear relation between BMI and invasive mechanical ventilation (OR 1.27 per 5 kg/m 2 ) and a significant association between BMI and mortality, which was only increased in obesity class III (≥40 kg/m 2 ) (HR 1.68). 12 In a study of 6916 patients with COVID-19, there was a J-shaped association between BMI and risk for death, even after adjustment for obesity-related comorbidities. 13 Patients with BMI of [40] [41] [42] [43] [44] kg/m 2 had a relative risk (RR) of 2.68, and those with BMI >45 kg/m 2 had an RR of 4.18 compared with patients with BMI of 18.5-24 kg/m 2 . This risk was most striking among those aged <60 years and men. A J o u r n a l P r e -p r o o f study aiming to identify risk factors for severe COVID-19 disease in 158 African-Americans, indicated that patients admitted to ICU were older (62 vs. 55 years, P=0.003) and had higher BMI (36.5 kg/m 2 vs. 31 .9 kg/m 2 , P=0.002). 14 In multivariate analysis, the factors most associated with ICU-admission were age (adjusted odds ratio-aOR: 1.073), BMI (aOR: 1.115) , and lung disease (aOR: 3.097).

A retrospective study of 3530 hospitalized patients with COVID-19 disease (median age 65 years; women ~45%; median BMI 28.8 kg/m 2 ) showed a J-shaped association between BMI and in-hospital mortality. 15 In men, BMI 35-39.9 kg/m 2 and BMI ≥40 kg/m 2 had a significant association with higher inhospital mortality, while only BMI ≥40 kg/m 2 was found significant in women. Obesity classes II and III in men and obesity class III in women were independently associated with higher in-hospital mortality in patients with COVID-19.

Another retrospective study of 3,406 hospitalized COVID-19 patients indicated that in the younger (<50) age group (n=572, 17%), 60 (10.5%) patients died, while in the older age group, 1,076 (38%) patients died. 16 For the younger population, BMI ≥ 40 was independently associated with mortality (aOR 5.1) and to a lesser extent for the older group (aOR 1. 6 ).

An observational study followed 10,861 patients with COVID-19 infection, comprising 243 (2.2%) patients who were underweight, 2,507 (23.1%) with normal weight, 4,021 (37.0%) having overweight, 2,345 (21.6%) with obesity class I, 990 (9.1%) with obesity class II, and 755 (7.0%) with obesity class III. 17 Patients who had overweight (OR 1.27), obesity class I (OR 1.48), obesity class II (OR 1.89), and obesity class III (OR 2.31) had an increased risk of requiring invasive mechanical ventilation (IMV). Underweight (OR 1.44) and obesity classes II (OR 1.25) and III (OR 1.61) conferred increased risk of death. Among patients who were on IMV, BMI was not associated with inpatient deaths. The authors concluded that COVID-19 patients who are underweight or who have obesity are at risk for mechanical ventilation and death.

A retrospective cohort study of 1,019 SARS-CoV-2 positive patients (median age 64 years, 58.7% men, prevalence of overweight and obesity 75.2%; median BMI 28.5 kg/m 2 ) showed by multivariable logistic regression that BMI was associated with complications including intubation (OR 1.03), septic shock (OR 1.04), renal replacement therapy (OR1.07), and mortality (OR 1.04). 18 The odds of death were highest among those with BMI ≥ 40 kg/m 2 (OR 2.05). The authors concluded that severe complications of COVID-19 and death are more likely in patients with obesity, independent of age and comorbidities.

A study examining the link between BMI and risk of a positive test for COVID-19 infection and risk of COVID-19-related death among 4855 UK Biobank participants, of whom 839 were positive and of J o u r n a l P r e -p r o o f these 189 died from COVID-19, showed that BMI was associated strongly with positive test, and risk of death related to COVID-19. 19 The BMI-related risk was higher in those under 70.

A large prospective, community-based cohort study comprising 6,910,695 individuals (mean BMI 26.78 kg/m 2 ), of whom 13,503 (0.20%) were admitted to hospital, 1601 (0.02%) to an ICU, and 5479 (0.08%) died after a positive test for SARS-CoV-2, found a J-shaped association between BMI and admission to hospital due to COVID-19 (adjusted hazard ratio -aHR per kg/m 2 from the nadir at BMI of 23 kg/m 2 of 1.05) and death (aHR 1.04), and a linear association across the whole BMI range with ICU admission (aHR 1.10). 20 There was also significant interaction between BMI and age and ethnicity, with higher HR per kg/m 2 above BMI 23 kg/m 2 for younger people (aHR per kg/m 2 24 These results were confirmed in a larger study of 2466 COVID-19 patients. 25 Patients, particularly those <65 years, with BMIs >30kg/m 2 were more likely to be intubated or die. These findings were further corroborated by an analysis of BMI stratified by age in 3615 COVID-19-patients. 26 Patients aged < 60 years with a BMI of 30-34 were 1.8-2.0 times more likely and those with BMI ≥ 35, 2.2-3.6 times more likely to be admitted to ICU, compared to individuals with a BMI<30.

J o u r n a l P r e -p r o o f Thus, in the younger age-group of < 60 years who are generally considered a lower-risk group of COVID-19 severity, obesity seems to negate this age-advantage and becomes a risk factor for hospital admission and need for ICU monitoring. [24] [25] [26] This has practical implications for countries with high prevalence of obesity, like the US where ~40% or the UK where ~30% of adults are obese (BMI≥ 30). 27, 28 Importantly, even in the young, particularly in adolescents, obesity has been shown to be an independent risk factor for critical illness. 29 In summary, obesity is a risk factor for COVID-19 hospital admission and an independent risk factor of severe illness, including respiratory failure and need for intubation and ICU care. Importantly, obesity is an independent risk factor for poor outcomes including intubation and death in younger (<65-45 years), mostly male, patients, an age-group generally considered a lower-risk group of COVID-19 disease severity, a privilege that is cancelled-out by obesity. Furthermore, more severe obesity, central obesity, or genetic predisposition for obesity confer higher risk of severe-COVID-19. 30, 31 Higher BMI levels are associated with higher risk of contracting COVID-19. 32 Interestingly, COVID-19 patients who are underweight are also at risk for mechanical ventilation and death (see discussion below).

Meta-analyses of studies comparing obese vs non-obese patients with COVID-19 are included in Table 2 . A meta-analysis of 9 studies comprising 6577 patients indicated that for patients with severe complications, the overall pooled-event rates were highest at 56.2% (p=0.015; I 2 =71.5) for obesity. 33 Similar findings were obtained from another meta-analysis of 34 studies reporting on comorbidities in COVID-19 patients. 34 In patients with severe/fatal COVID-19, the most prevalent chronic comorbidity was obesity (42%). The pooled OR for prediction of severe or fatal outcomes was strongest for chronic respiratory disease (OR 3.56), and still quite strong for obesity (OR 1.72).

Another meta-analysis of 12 studies (N=34,390) demonstrated that obesity was associated with poor composite outcome (mortality and severity) (OR 1.73, P<0.001; I 2 :55.6%), mortality (OR 1.55, P=0.003; I 2 :74.4%), and clinical severity (OR 1.90, P<0.001; I 2 :5.2%) in patients with COVID-19. 35 A pooled analysis of highest vs reference BMI indicated that a higher BMI was associated with composite poor outcome (aOR 3.02), mortality (aOR 2.85), and severity (aOR 3.08).

A meta-analysis of 20 studies (N=7671) indicated higher rates of complications among people with obesity. 36 A meta-analysis of 14 studies (N=26,507) indicated higher mortality (21.7%) among patients with BMI >25kg/m 2 vs patients (7.1%) with BMI<25kg/m 2 (P=0.005, OR 3.68). 37 According to a meta-analysis of 24 studies, obesity was a risk factor for ICU admission (OR=1.21; I 2 =0%) and invasive mechanical ventilation (OR=2.05; I 2 =34.9%) in COVID-19. 38 A higher BMI carries a J o u r n a l P r e -p r o o f higher risk. 38, 39 Other meta-analyses also showed an association between obesity and COVID-19 severity and poor outcomes; [40] [41] [42] [43] also, excessive visceral adiposity is associated with poor COVID-19 outcomes. 41 A large meta-analysis of 75 studies (N=399 461; ~55% male) showed that individuals with obesity were more at risk for COVID-19 positive, >46% higher (OR 1.46; P<0.0001); for hospitalization, 113% higher (OR 2.13; P<0.0001); for ICU admission, 74% higher (OR 1.74); and for mortality, 48% increase in deaths (OR 1.48; P<0.001). 44 A major concern was expressed by the authors that vaccines may be less effective for the individuals with obesity.

A recent meta-analysis of 22 studies indicated that obesity is associated with an increased likelihood of presenting with more severe COVID-19 symptoms ( 46 Similar findings were reported by another recent meta-analysis (217 observational studies, N=624,986) examining the predictive value of chronic diseases for COVID-19 severity and mortality; patients with obesity were at a higher risk of experiencing severe symptoms of COVID-19 (OR 2.63) rather than mortality. 47 Also, a meta-analysis of 12 studies, comprising 405,359 patients, showed that the pooled risk of COVID-19 severity was 1.31 times higher based on both fixed and random effect model among those overweight patients (I 2 0%) and 2.09 and 2.41 times higher based on fixed and random effect respectively among obese patients (I 2 42%) compared to healthy individuals. 48 A meta-analysis of 4752 hospitalized adult overweight/obese patients with COVID-19 from 18 sites in 11 countries showed that overweight patients were more likely to require oxygen/noninvasive ventilatory support (random effects adjusted odds ratio -aOR, 1.44) and invasive mechanical ventilatory support (aOR, 1.22). 49 There was no association between overweight and in-hospital mortality (aOR, 0.88). Similar effects were noted in patients with obesity.

A meta-analysis of 28 studies comprising 112,682 COVID-19 patients showed that those with a high BMI had an elevated risk of mortality (pooled RR 1.33; P< 0.001), with moderate heterogeneity (I 2 = 54.2%). 50 A positive dose-response association between BMI and mortality was found based on the linear model. However, a significant nonlinear relationship between BMI and mortality was observed. A J o u r n a l P r e -p r o o f J-shaped curve was noted, indicating that both underweight and obese patients had a higher mortality than those with normal weight. A BMI of ~27 kg/m 2 appeared to confer the lowest mortality risk. In the sensitivity analysis of studies with data on underweight patients (n=13), the J-shaped relationship between BMI and mortality remained unchanged. Similar findings were shown by additional meta-analyses (Table 2) . 51, 52 In general, metaanalyses indicate that individuals with obesity seem to be at higher risk for serious illness when infected with COVID-19 and obesity seems to play a role in the progression and prognosis of COVID-19, with linear dose-response association between BMI and both COVID-19 severity and mortality; a higher degree of obesity may predict a higher risk. 39, [53] [54] [55] [56] Obesity as a risk factor may be greater in younger patients. 57 Furthermore, genetic evidence supports higher BMI as a causal risk factor for COVID-19 susceptibility and severity. 58 Importantly, a non-linear association between BMI and the severity of COVID-19 has been demonstrated, 59 with obese and underweight persons being at increased risk (see discussion below).

In summary, in keeping with the results of individual studies, metanalyses indicate a strong relationship between obesity, ICU admission, severe COVID-19, disease progression and mortality in patients with COVID-19; the higher the BMI the worse the clinical outcomes.

Overweight and obesity are independent risk factors of severe illness and respiratory failure in COVID-19 patients. 23 In a retrospective analysis of 140 COVID-19 patients with ARDS admitted to ICU who were compared with 247 'other ARDS' patients, BMI was higher in COVID-ARDS patients (median 28 vs 25 kg m −2 , P<0.0001). 60 More patients with overweight (BMI 25-29.9 kg/m 2 ) and obesity (BMI ≥30kg/m 2 ) in COVID-ARDS group were admitted to ICU (49% vs 33% and 29% vs 16%, respectively; P<0.0001). Strong associations were found between COVID-ARDS and male sex and with patients with overweight/obesity. As mentioned, a dose-response meta-analysis showed that increased BMI was associated with poorer outcome in COVID-19 patients; the curve became steeper with increasing BMI. 35 Among 383 hospitalized COVID-19 patients, compared with normal-weight patients, patients with overweight had 1.84-fold odds of developing severe COVID-19 (P=0.05), while patients with obesity were at 3.40-fold odds of developing severe disease (P=0.007), after adjusting for age, sex, other comorbidities, and drug treatment. 61 Also, men with obesity were at increased odds of developing severe COVID-19 (OR 5.66, P=0.003). In another study, obesity was associated with ~6-fold increased risk and need for invasive mechanical ventilation. 62 A study of 100 patients with COVID-19 pneumonia J o u r n a l P r e -p r o o f indicated that patients with obesity (n=29) required longer hospitalization, more intensive and longer oxygen treatment, and had longer virus-shedding. 63 A study of 770 patients reported that obesity was associated with an increased risk of critical illness with higher rate of ICU admission or death compared to normal-weight patients (RR=1.58, p=0.002) even after adjusting for age, race and troponin level. 64

In patients dying with COVID-19 in Italy, particularly in those aged <60 years, obesity was shown to be associated with more non-respiratory complications, particularly shock (aOR 1.54; aOR 2.00 in young adults) and acute renal failure (aOR 1.33; aOR 2.37 in young adults). 65 As mentioned, a metaanalysis of 9 studies (N=6577) indicated that COVID-19 patients with obesity had the highest overall pooled-event rates for severe complications (56.2%, p=0.015). 33 However, results are not consistent across studies regarding particular complications. As mentioned, a study of 504 patients, stratified according to BMI, indicated that COVID patients with overweight (RR 2.0) and obesity (RR 2.4) had an increased relative risk for intubation, but obesity did not affect rates of acute kidney injury, acute cardiac injury, or ARDS. 21 Nevertheless, increased mortality was observed in patients with overweight (RR 1.4) and obesity (RR 1.3) compared with those with normal BMI.

As mentioned, most of the studies and meta-analyses have reported a significantly higher mortality-risk in COVID-19 patients with overweight and obesity compared with patients with normal BMI. 7, 13, 21, 24, 25, [35] [36] [37] In a French prospective study including 5795 patients aged 18-79 years, obesity doubled mortality in patients hospitalized with COVID-19; OR 1.89 for BMI 30-35, 2.79 for BMI 35-40 and 2.55 for BMI >40kg/m 2 (18.5-25 kg/m 2 was the reference-class); this increase held true for all agegroups. 66 As mentioned, recent analysis of COVID-mortality related factors in various countries indicated that obesity was the second-best predictor of death rate after the GDP. 9

Some investigators suggest that adipose tissue is playing crucial role and therefore it is necessary to evaluate fat-mass and not simple BMI. A prospective study of 22 patients, affected by COVID-19 pneumonia and admitted to the ICU, discerned two groups, lean (n=10) and obese (n=12), according to percentage of fat mass (FM%). 67 They noted that patients with obesity had a reduced survival.

Other investigators have suggested that visceral adipose tissue (VAT) fat is more specifically the marker of worse clinical outcomes in patients with COVID-19. 68, 69 In a retrospective study of 150 COVID-19 patients undergoing a chest computed tomography (CT) scan, VAT was higher in patients requiring intensive care (P=0.032). 70 Multivariate analysis showed that Lung Severity Score and VAT were independently associated with the need of intensive care (OR: 1.262; P=0.005 and OR: 2.474; P=0.046, respectively). A meta-analysis of 5 studies comprising 539 patients showed that visceral, but not subcutaneous, adiposity was associated with increased COVID-19 severity (OR 1.9, P=0.002; I 2 49.3%). 69 Other investigators have attributed worse prognosis in ARDS patients to higher visceral/subcutaneous adipose tissue ratio, rather than just higher VAT. 71, 72 Furthermore, the cardiometabolic risk can also be predicted by other unhealthy fat distribution indicated by impaired ability to expand subcutaneous fat in the lower part of the body, in the gluteofemoral region and in the legs. 73 Such pattern of lower-body fat mass distribution is equally important to a high amount of visceral fat mass as a determinant of cardiometabolic diseases. In a similar context, data from the UK Biobank have indicated that anthropometric indices that are more sensitive to adipose volume and its distribution than BMI, as well as concomitant cardiometabolic disorders, are associated with higher odds of COVID-19-related mortality. 74 Regarding the pathophysiology underlying the suggested link between obesity and severity of COVID-19, investigators consider it multifactorial (Fig. 1) . One aspect is attributed to the association of obesity with complement-system hyperactivation, chronic inflammation, and presence of comorbidities proposed in turn to be risk-factors for COVID-19 poor prognosis. 75 A more specific link may relate to the fact that VAT is capable of secreting pro-inflammatory cytokines which might augment the deleterious effects of COVID-19; 76 VAT produces interleukin (IL)-6 at 2 to 3-fold higher levels than subcutaneous fat; 77, 78 IL-6 levels have been found to be increased in COVID-19 non-survivors. 79 Furthermore, as COVID-19 has been shown to infect cells through an angiotensin-converting enzyme 2 (ACE2)-dependent mechanism, this receptor is also expressed by fat, including ectopic reservoirs, e.g., epicardial adipose tissue, 80 indicating an additional direct proinflammatory role of COVID-19 in the adipose tissue that may thus possibly contribute to such detrimental effects of the virus. Some investigators have ascribed the elevated risk for hospital admission in COVID-19 patients with obesity to mechanisms involving impaired glucose and lipid metabolism. 11 In this context, a study of 640 COVID-19 patients, indicated an upward linear trend in the likelihood of COVID-19 hospitalization with increasing BMI, which was little affected after adjustment for several covariates. 11 Interestingly, metabolic dysfunction-associated fatty J o u r n a l P r e -p r o o f liver disease has been suggested as a surrogate for COVID-19 severity due to the accumulation of associated metabolic changes, representing a higher risk than obesity per se for COVID-19 severity . 81 There is evidence of smoldering chronic inflammation during obesity in the absence of an apparent infection or a specific autoimmune disease process. [82] [83] [84] In this context, there are data that the Nod-like receptor (NLR) family of innate immune-cell sensors, such as the pyrin domain-containing-3 (Nlrp3, also known as cryopyrin) inflammasome, senses obesity-associated danger-signals and contributes to obesity-induced inflammation and insulin-resistance. 85 Furthermore, COVID-19 leads to activation of both innate and adaptive immunity after recognition of viral antigens and produces a large amount of pro-inflammatory cytokines even in moderate cases; in some patients, this activation becomes exuberant and leads to a 'cytokine storm', with ensuing severe lung injury, multiple-organ failure and, ultimately, death. 86, 87 In this framework, the co-existence of the two conditions, obesity and COVID, may lead to hyperinflammation which can exacerbate these deleterious processes with dire consequences. 84, 87 The findings of a recent study support the involvement of systemic inflammatory pathways in obesity associated severe COVID-19 infection, especially in younger (<65 years) patients, as reflected by increased C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). 88 Specifically, in one cohort of this study (n=1202), obesity was associated with increased likelihood of mechanical ventilation or death (odds ratio-OR 1.73, P<0.001) and higher peak of CRP compared with nonobese patients. The estimated proportion of the link between obesity and ventilation or death mediated by CRP was 0.49 (P<0.001), more pronounced in patients younger than 65 years (P<0.001). Similar results, albeit more moderate but consistent, were reported for peak ESR. Findings were replicated by a larger second cohort (n=2626).

Another parameter that has been suggested as an important factor in weakening immune response and thus predisposing patients with obesity to the COVID-19 ailments is the leptin-resistant state. Leptin is a cytokine produced in adipose tissue in amounts commensurate with adipose tissue mass. Leptin, among other functions, regulates metabolic homeostasis but also supports immune function by modulating both innate and adaptive immune responses. 89 However, obesity is characterized by leptin-resistance which leads to increased leptin levels, albeit with failure to promote its inherent actions that modulate a host of physiologic processes. Thus, leptin-resistance confers dysregulation of cytokine production and increased susceptibility toward inflammatory responses and infectious and viral diseases 90 . Furthermore, diminished leptin-signaling may enhance J o u r n a l P r e -p r o o f immunosuppression by T-regulatory cells and render the host immunity incompetent to manage pathogens' attack and invasion, resulting in accelerated infection and attenuated vaccine-specific antibody response. 91 Interestingly, there is evidence that leptin is not only expressed in adipose tissue but also in several organs, including the lungs. 92 In addition to adipose tissue overexpressing the receptors (ACE2) and proteases for viral entry, obesity may also compromise motile cilia on airway epithelial cells and impair functioning of the mucociliary escalators (the apparatus of mucus and cilia responsible for expelling of mucus from the respiratory tract), thus reducing the clearance of severe COVID-19. 95 Other investigators have stressed the potential role of an increased sympathetic nervous system (SNS) activity that characterizes several comorbidities, including obesity, which may exert significant deleterious effects on COVID-19 patients, through actions on the lungs, heart, blood vessels, kidneys, metabolism, and/or immune system. [96] [97] [98] Furthermore, COVID-19 can certainly increase SNS discharge, through changes in blood gases (hypoxia, hyperpnea), ACE1/ACE2 imbalance, immune/inflammatory factors, or emotional distress. Thus, an interplay between obesity-and COVID-19-induced SNS overactivity, leading to a vicious circle between COVID-19 and obesity and/or other comorbidities, could offer an explanation for a potential link between obesity and COVID-19.

Obesity also affects cardiorespiratory reserve by reducing forced expiratory volume and forced vital capacity. 76 Thus, obesity leads to compromised lung function and furthermore to poor response to mechanical ventilation, with consequential high risk of severe illness and mortality from COVID-19. 99 Furthermore, it has been documented that obesity enhances venous and pulmonary thromboembolism, 100 while COVID-19 also predisposes patients to arterial and venous thrombosis. 101 Importantly, in COVID patients, pulmonary embolism may occur even in the absence of a recognizable deep venous thrombosis and may be due to pulmonary arterial thrombosis rather than embolism. 102 Thus, the thrombotic risk may be greatly exacerbated in patients with obesity and COVID-19 and may raise mortality, particularly in critically-ill patients.

In addition, it should be noted that obesity, and more so, extreme obesity (e.g., BMI>40 kg/m 2 ), may compromise care for patients with obesity managed in the ICU, as these patients are more difficult to image, ventilate, nurse, and rehabilitate. 76 Prone positioning, known to ameliorate patient aeration and oxygenation, presents more challenges and possible complications in patients with obesity. 103, 104 Importantly, one needs to also take into account that individuals with obesity have many associated comorbidities in the form of metabolic syndrome and beyond, 105 which greatly increase their health risk and invite a variety of metabolic, CV, respiratory and other complications when these patients are afflicted by COVID-19. 106, 107 Finally, the two diseases (obesity and COVID-19) appear to be interconnected, as the COVID-19 pandemic has been shown to exacerbate the obesity epidemic among adult and pediatric populations due to physical inactivity, stress and unhealthy diet; 108-110 on the other hand, obesity and impaired metabolic health are enhancers of severe COVID-19 infection. 109 Also, obesity might adversely affect the efficacy of COVID-19 vaccines due to reduced memory immune responses in these individuals leading to diminished long-term protection against re-infections; 111 hence, investigators propose strategies for the prevention and treatment of obesity and impaired metabolic health in the community during the COVID-19 pandemic. 109 On another note, long COVID emerges as an important post-acute sequela of COVID-19 infection, comprising a broad array of incident pulmonary and extrapulmonary clinical manifestations, 112 and in this context, an excess burden of several metabolic disorders becomes evident, including lipid metabolism (HR 12.32), diabetes mellitus (HR 8.23) and obesity (HR 9.53). 113 On the other hand, high BMI and previous pulmonary disease have been indicated as risk factors for the development of long COVID. 114 In addition, obesity has been associated with a greater number of long-term post-COVID symptoms and poor sleep quality in hospitalized COVID-19 patients. 115 

There are individuals who have excessive body fat, particularly VAT, despite a normal BMI. 116 These individuals may have a metabolic syndrome-like profile (higher levels of insulin and/or insulinresistance, diabetes, hypertension, hypertriglyceridemia) and higher risk of atherosclerotic CVD, while their adipose tissue, usually VAT, may express higher levels of pro-inflammatory cytokines. 28, 76 As mentioned, evaluating percentage of fat mass, rather than BMI, in COVID-19 patients, a number of patients with normal BMI could actually have an excess of adipose tissue and therefore have an unfavorable outcome similar to the obese patients. 67 Importantly, ectopic obesity, localized beyond the subcutaneous adipose tissue where there is increased local fat distributed in visceral, perivascular, and epicardial adipose tissue, seems to also promote chronic proinflammatory, prothrombotic, and vasoconstrictive states, which can manifest as insulin-resistance, diabetes, hypertension, CVD and immunocompromised state. 13, 76, 117, 118 As mentioned, VAT also promotes increased mortality among critically-ill patients with ARDS. 71 In this context, ectopic fat and COVID-19 seem to share a common link converging in the upregulation of proinflammatory, prothrombotic, and vasoconstrictive states, thus enhancing the cumulative deleterious effects of both diseases (obesity and COVID).

In the context of metabolically unhealthy normal weight individuals, it is important to discern other phenotypes that characterize this population. One such phenotype is the lipodystrophy-like phenotype noted in lean persons with increased glucose, dyslipidemia, and hypertension, parameters commonly used to identify the metabolic risk, that may be more strongly associated with a relatively low gluteofemoral-and leg-fat mass than with high subcutaneous abdominal fat mass, visceral obesity, or fatty liver; also this phenotype is strongly characterized by reduced insulin secretion and insulin resistance, low cardiorespiratory fitness, and increased carotid intima media thickness (cIMT), a surrogate of atherosclerosis. 119 Genetic analyses indicate that metabolic risk appears to be determined by different pathways in normal weight and obese individuals, with all such findings having several implications for clinical and drug interventions. Thus, compared with individuals who are of normal weight and metabolically healthy, those who are of normal weight but metabolically unhealthy (∼20% of the normal weight adult population) have a >3-fold elevated risk of all-cause mortality and/or CV events. 119 Importantly there is evidence that lipodystrophy might result in nonalcoholic fatty liver disease (NAFLD). 120, 121 NAFLD is not only associated with liver-related complications, but also with adverse cardiometabolic outcomes. 122 Within this pathogenesis, 122, 123 NAFLD may increase the risk of complications in COVID-19. In this context, a recent large study showed that NAFLD was associated with J o u r n a l P r e -p r o o f a higher risk of COVID-19 infectivity and severity among 74,244 individuals who underwent SARS-CoV-2 testing. 124

In addition to obesity, underweight also confers a health risk. 125 According to a large cohort study, a U-shaped association between BMI and all-cause mortality was observed in men and women.

Compared with the normal-BMI group, an increased risk was found both in the highest BMI (>35 kg/m 2 , HR 2.13 in men and 1.60 in women), driven by CVD and cancer, and in the lowest BMI (<18.5 kg/m 2 , HR of 2.57 in men and 1.40 in women), 125 driven by respiratory diseases independently from smoking status.

As mentioned, a retrospective study of 6916 patients with COVID-19 also pointed to a J-shaped association between BMI and risk for death, even after adjustment for obesity-related comorbidities. 13 In particular, the risk ratio (RR) for death was 1. 81 . This J-curve relationship was similar when patients were stratified by age and gender, albeit with lack of data for underweight younger (<60) patients. A J-shaped association between BMI and death or intubation was also revealed by another study (N=2466), with an inflection point of predicted risk at a BMI of 30 kg/m 2 ; patients who were underweight and those with BMIs above the overweight range were more likely to be intubated or die than those who were simply overweight. 25 However, most studies do not provide data for the underweight, while a smaller study refutes these findings. 61 Regarding the mechanism of underweight-conferred health risk, the associated lipodystrophy, when present, may provide one plausible explanation. Lipodystrophies are hypoleptinemic disorders characterized by fat loss, severe insulin resistance, hypertriglyceridemia, and ectopic fat accumulation. 126 Non-alcoholic fatty liver disease (NAFLD) and steatohepatitis (NASH) are features of lipodystrophy 120, 126 and within this pathogenesis, 122, 123 lipodystrophy may increase the risk of complications in COVID-19. 127, 128 In summary, BMI is a strong predictor of clinical outcomes in the era of the COVID-19 pandemic.

In this context, one could stress the deleterious liaison formed between obesity and COVID-19, especially in the younger population (<60 years), but could not also ignore the harmful effect of the underweight state in this relationship and therefore this risk could be depicted as a J-curve, where the J o u r n a l P r e -p r o o f strongest evidence, at least for cardiorespiratory problems, lies with the overweight/obese/severely obese, but reliable evidence also points to the risk incurred in the underweight individuals (Fig. 2) .

Obesity or excessive localized fat, like VAT, may pose a significant risk in patients with COVID-19.

This risk factor apparently reduces protective cardiorespiratory reserve and enhances immune dysregulation that paves the way to disease progression to critical illness and organ failure. It also appears that obesity is an independent risk-factor for susceptibility to COVID-19, disease severity, complications and mortality. The risk is higher for younger (<60 years) individuals, where the age-related lower risk observed in normoweight individuals seems to be cancelled-out in patients with obesity. Less, albeit solid, evidence also exists for a higher risk of COVID-19 incurred in individuals who are underweight. Thus, the relationship of COVID-19 and BMI seems to follow a J-curve pattern. However, ectopic obesity in individuals who are either normoweight or overweight/obese needs also to be taken into consideration, as the accumulation of fat in visceral, perivascular, and epicardial adipose tissue, seems to also promote chronic proinflammatory, prothrombotic, and vasoconstrictive states with their attendant adverse clinical outcomes in COVID-19 patients.

Expression of enzymes by adipose tissue, like ACE2, that facilitate viral entry, as well as multiple other adipose tissue-related mechanisms may contribute to development and progression of COVID-19, via complex interactions between the immune system and adipose tissue. 129 The overexpression of inflammatory adipokines from VAT can affect the immune response, impair chemotaxis, and alter macrophage differentiation. It is therefore logical that investigators have proposed therapeutic strategies targeting the adipose tissue as a countermeasure. However, some options, like ACE2 blockade, may prove to be a double-edged sword. 130 Human dipeptidyl peptidase 4 (DPP4), a transmembrane protein, was identified as a functional receptor for the spike protein of the Middle East respiratory syndrome (MERS)-coronavirus, 131 and may have a similar function in COVID-19. 129 DPP4 has been identified in human adipose tissue and is associated with obesity-related diabetes; its inhibition increases glucagon-like peptide-1 secretion, and improves insulin sensitivity and glucose metabolism within fat cells. DPP4 inhibition could therefore play a role in the immune response to COVID-19 by reducing inflammation via suppression of T-cell proliferation and the secretion of proinflammatory cytokines, such as IL-6. 129, 132 Thus, the use of DPP4inhibitor drugs (gliptins) in patients with COVID-19 with or without diabetes, including patients with J o u r n a l P r e -p r o o f obesity, might reduce the virus entry and replication into the respiratory system and prevent or mitigate cytokine-storm and lung inflammation in these patients. 133 Individuals with obesity have been found to have higher levels of tumor-necrosis factor-alpha (TNF-α), IL-6 and other cytokines, all of which are produced by macrophages emanating from the adipose tissue. Hence, the suggestion that TNF-α and/or IL-6-inhibitors might be of value in these patients to counteract these proinflammatory effects. 134 As mentioned, leptin-resistance characterizes the overweight/obese state, and is implicated in dysregulation of cytokine production and increased susceptibility toward inflammatory responses and infectious diseases. 90 Whether the antiobesogenic effect of agents, like melatonin, could restore leptin-resistance in individuals with obesity remains to be seen. 135 With regards to therapeutic strategies addressing the ectopic fat, epicardial fat has been shown to respond to thiazolidinediones, glucagon-like peptide-1 receptor agonists, DPP4-inhibitors and statins. 136 Abdominal VAT may respond to statins, metformin, sibutramine, orlistat, growth-hormone-releasing hormone analogue (tesamorelin), melatonin, etc.; however, there remain several important issues with these agents that relate to side-effects, inefficacy, rebound effect, etc. 137 However, these are not agents that could be used in the setting of an acute infection, like COVID-19, except perhaps for DPP4inhibitors and statins. 133, 138 They may be considered in the big picture of obesity management to normalize regulatory and cardiometabolic abnormalities associated with obesity and to complement dietary and exercise strategies. According to a recent systematic review on the role of nutrition in COVID-19 susceptibility and severity of disease, there is strong evidence that prevention of obesity and type 2 diabetes will reduce the risk of serious COVID-19 outcomes. 139 The estimated proportion of the link between obesity and ventilation or death mediated by CRP was 0.49 (P<0.001), more pronounced in pts <65 years (P<0.001) ACI = acute cardiac injury; aHR = adjusted hazard ratio; AKI = acute kidney injury; aOR = adjusted odds ratio; ARDS = acute respiratory distress syndrome; BMI = body mass index; COPD = chronic obstructive pulmonary disease; CRP = C-reactive protein; CVD = cardiovascular disease; ESR = erythrocyte sedimentation rate; HR = hazard ratio; ICU = intensive care unit; IL-6 = interleukin-6; IMV = invasive mechanical ventilation; pts = patients; OR = odds ratio; qSOFA = quick sepsis-related organ failure assessment (score); RR = relative risk The pooled prevalence of obesity was 27.6% in hospitalized pts aOR = adjusted odds ratio; ARDS = acute respiratory distress syndrome; ARS = advanced respiratory support; BMI = body mass index; CVD = cardiovascular disease; IMV = invasive mechanical ventilation; MR = mortality rate; NA = not available; NR = not reported; OR = odds ratio; pts = patients; RR = risk ratio; VAT = visceral adipose tissue

Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China

Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease

Cardiovascular Complications of the Coronavirus (COVID-19) Infection

Body Mass Index and Mortality in Subjects With ARDS: Post-hoc Analysis of the OSCILLATE Trial

Can body mass index predict clinical outcomes for patients with acute lung injury/acute respiratory distress syndrome? A meta-analysis

Obesity Paradox" in Acute Respiratory Distress Syndrome: Asystematic Review and Meta-Analysis

Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study

High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical Ventilation

Obese communities among the best predictors of COVID-19-related deaths

Body Mass Index and Mortality in Coronavirus Disease 2019 and Other Diseases: A Cohort Study in 35,506 ICU Patients

Overweight, obesity, and risk of hospitalization for COVID-19: A community-based cohort study of adults in the United Kingdom

BMI and pneumonia outcomes in critically ill COVID-19 patients: an international multicenter study

Obesity and Mortality Among Patients Diagnosed With COVID-19: Results From an Integrated Health Care Organization

Intensive Care Unit Admission in African Americans

Sex-specific impact of severe obesity in the outcomes of hospitalized patients with COVID-19: a large retrospective study from the Bronx

Severe Obesity as an Independent Risk Factor for COVID-19

Mortality in Hospitalized Patients Younger than 50

BMI as a Risk Factor for Clinical Outcomes in Patients Hospitalized with COVID-19 in New York

Obesity is independently associated with septic shock, renal complications, and mortality in a multiracial patient cohort hospitalized with COVID-19

BMI and future risk for COVID-19 infection and death across sex, age and ethnicity: Preliminary findings from UK biobank

Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study

The impact of obesity on COVID-19 complications: a retrospective cohort study

How important is obesity as a risk factor for respiratory failure, intensive care admission and death in hospitalised COVID-19 patients? Results from a single Italian centre

Overweight and obesity are risks factors of severe illness in patients with COVID-19

In Young Adults with COVID-19, Obesity Is Associated with Adverse Outcomes

Body Mass Index and Risk for Intubation or Death in SARS-CoV-2 Infection: A Retrospective Cohort Study

Obesity in Patients Younger Than 60 Years Is a Risk Factor for COVID-19 Hospital Admission

Prevalence of Obesity Among Adults, by Household Income and Education -United States

Obesity and covid-19: the unseen risks

Age-dependent association of obesity with COVID-19 severity in paediatric patients

Association of obesity and its genetic predisposition with the risk of severe COVID-19: Analysis of population-based cohort data

The impact of obesity on severe disease and mortality in people with SARS-CoV-2: A systematic review and meta-analysis

Association between Body Mass Index and Risk of COVID-19: A Nationwide Case-Control Study in South Korea

SARS-CoV-2) and the risk of obesity for critically illness and ICU admitted: Meta-analysis of the epidemiological evidence

Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-analysis

Body mass index and outcome in patients with COVID-19: A dose-response meta-analysis

Impact of obesity on hospitalizations and mortality, due to COVID-19: A systematic review

Obesity and mortality of COVID-19. Metaanalysis

Obesity is a risk factor for developing critical condition in COVID-19 patients: A systematic review and meta-analysis

Association of Body mass index (BMI) with Critical COVID-19 and in-hospital Mortality: a dose-response meta-analysis

Effect of increased BMI and obesity on the outcome of COVID-19 adult patients: A systematic review and meta-analysis

Obesity in patients with COVID-19: a systematic review and meta-analysis

Obesity a predictor of outcomes of COVID-19 hospitalized patients-A systematic review and meta-analysis

Effect of obesity and body mass index on coronavirus disease 2019 severity: A systematic review and meta-analysis

Individuals with obesity and COVID-19: A global perspective on the epidemiology and biological relationships

A systematic review and meta-analysis of obesity and COVID-19 outcomes

The association between obesity and ICU admission among COVID-19 patients: A meta-analysis of adjusted risk estimates

Chronic Diseases as a Predictor for Severity and Mortality of COVID-19: A Systematic Review With Cumulative Meta-Analysis

Does higher body mass index increase COVID-19 severity? A systematic review and meta-analysis

Diabetes and Overweight/Obesity Are Independent, Nonadditive Risk Factors for In-Hospital Severity of COVID-19: An International, Multicenter Retrospective Meta-analysis

The J-shaped relationship between body mass index and mortality in patients with COVID-19: A dose-response meta-analysis

Obesity and Mortality Among Patients Diagnosed With COVID-19: A Systematic Review and Meta-Analysis

Obesity in COVID-19: A Systematic Review and Metaanalysis

Prevalence of Obesity and Its Impact on Outcome in Patients With COVID-19: A Systematic Review and Meta-Analysis

Obesity Increases the Severity and Mortality of Influenza and COVID-19: A Systematic Review and Meta-Analysis

Obesity aggravates COVID-19: An updated systematic review and meta-analysis

Obesity is Associated with Poor Covid-19 Outcomes: A Systematic Review and Meta-Analysis

Obesity is associated with increased severity of disease in COVID-19 pneumonia: a systematic review and meta-analysis

Cardiometabolic risk factors for COVID-19 susceptibility and severity: A Mendelian randomization analysis

A meta-analysis of the association between obesity and COVID-19

Body mass index and acute respiratory distress severity in patients with and without SARS-CoV-2 infection

Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen

Obesity and Smoking as Risk Factors for Invasive Mechanical Ventilation in COVID-19: a Retrospective, Observational Cohort Study

Obesity prolongs the hospital stay in patients affected by COVID-19, and may impact on SARS-COV-2 shedding

Obesity is associated with worse outcomes in COVID-19: Analysis of Early Data From New York City

Non-respiratory Complications and Obesity in Patients Dying with COVID-19 in Italy

Obesity doubles mortality in patients hospitalized for SARS-CoV-2 in Paris hospitals, France: a cohort study on 5795 patients

Fat mass affects nutritional status of ICU COVID-19 patients

Visceral Adiposity Elevates the Risk of Critical Condition in COVID-19: A Systematic Review and Meta-Analysis

Visceral adiposity, subcutaneous adiposity, and severe coronavirus disease-2019 (COVID-19): Systematic review and meta-analysis

Visceral fat shows the strongest association with the need of intensive Care in Patients with COVID-19

High Visceral Adipose Tissue to Subcutaneous Adipose Tissue Ratio as a Predictor of Mortality in Acute Respiratory Distress Syndrome

Body composition predictors of outcome in patients with COVID-19

Causes, consequences, and treatment of metabolically unhealthy fat distribution

Increasing adiposity and the presence of cardiometabolic morbidity is associated with increased Covid-19-related mortality: results from the UK Biobank

Obesity and SARS-CoV-2: A population to safeguard

Obesity Is a Risk Factor for Severe COVID-19 Infection: Multiple Potential Mechanisms

Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid

Adipose Tissue Distribution, Inflammation and Its Metabolic Consequences, Including Diabetes and Cardiovascular Disease

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

ACE2/Ang 1-7 axis: A critical regulator of epicardial adipose tissue inflammation and cardiac dysfunction in obesity

Coronavirus disease 2019 severity in obesity: Metabolic dysfunction-associated fatty liver disease in the spotlight

Chronic inflammation in obesity and the metabolic syndrome

Obesity and inflammation: the linking mechanism and the complications

COVID-19 and the role of chronic inflammation in patients with obesity

The NLRP3 inflammasome instigates obesityinduced inflammation and insulin resistance

Pathophysiology of COVID-19: Mechanisms Underlying Disease Severity and Progression

The hidden role of NLRP3 inflammasome in obesityrelated COVID-19 exacerbations: lessons for drug repurposing

Understanding the link between obesity and severe COVID-19 outcomes: Causal mediation by systemic inflammatory response

Role of leptin as a link between metabolism and the immune system

Leptin Functions in Infectious Diseases

Emergence of Leptin in Infection and Immunity: Scope and Challenges in Vaccines Formulation

The Thousand Faces of Leptin in the Lung

Obesity and COVID-19: A Perspective from the European Association for the Study of Obesity on Immunological Perturbations, Therapeutic Challenges, and Opportunities in Obesity

The Controversy of Renin-Angiotensin-System Blocker Facilitation Versus Countering COVID-19 Infection

Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics

COVID-19 Infection and Cardiac Arrhythmias

The role of the autonomic nervous system in cardiac arrhythmias: The neuro-cardiac axis, more foe than friend?

Sympathetic activation: a potential link between comorbidities and COVID-19

COVID-19 and Obesity: Dangerous Liaisons

The effects of obesity on venous thromboembolism: A review

Viral Coagulopathy in Patients With COVID-19: Treatment and Care

Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome: Results From a Prospective, Single-Center

Early application of prone position for management of Covid-19 patients

Influence of abdominal obesity on multiorgan dysfunction and mortality in acute respiratory distress syndrome patients treated with prone positioning

Obesity and its comorbid conditions

Metabolic syndrome and COVID-19: An update on the associated comorbidities and proposed therapies

Obesity and Higher Risk for Severe Complications of Covid-19: What to do when the two pandemics meet

Unfavorable progression of obesity in children and adolescents due to COVID-19 pandemic: A school-based survey in China. Obesity (Silver Spring)

Global pandemics interconnected -obesity, impaired metabolic health and COVID-19

COVID-19 pandemic and stay-at-home mandates promote weight gain in US adults

COVID-19 infection, progression, and vaccination: Focus on obesity and related metabolic disturbances

Long COVID: An Emerging Puzzle

High-dimensional characterization of post-acute sequelae of COVID-19

Association between Long COVID and Overweight/Obesity

Obesity is associated with a greater number of long-term post-COVID symptoms and poor sleep quality: A multicentre case-control study

Normal-weight obesity syndrome: diagnosis, prevalence, and clinical implications

Adipose tissue, inflammation and atherosclerosis

Ectopic fat depots and cardiovascular disease

Causes, Characteristics, and Consequences of Metabolically Unhealthy Normal Weight in Humans

Lipodystrophic Nonalcoholic Fatty Liver Disease Induced by Immune Checkpoint Blockade

Fatty liver in lipodystrophy: A review with a focus on therapeutic perspectives of adiponectin and/or leptin replacement

Links between metabolic syndrome and metabolic dysfunctionassociated fatty liver disease

Non-alcoholic fatty liver disease: causes, diagnosis, cardiometabolic consequences, and treatment strategies

COVID-19 Morbidity and Severity in Patients With Nonalcoholic Fatty Liver Disease in South Korea: A Nationwide Cohort Study

Body mass index and mortality: results of a cohort of 184,697 adults in Austria

The liver diseases of lipodystrophy: the long-term effect of leptin treatment

Independent Predictors of Mortality Among Patients With NAFLD Hospitalized With COVID-19 Infection

Association of non-alcoholic fatty liver disease and COVID-19: A literature review of current evidence

Targeting the Adipose Tissue in COVID-19

Obesity and COVID-19: A Fatal Alliance

Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC

COVID-19 and diabetes: Can DPP4 inhibition play a role?

Dipeptidyl peptidase-4 (DPP4) inhibition in COVID

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Melatonin Absence Leads to Long-Term Leptin Resistance and Overweight in Rats

Epicardial fat: a new cardiovascular therapeutic target

Do we need anti-obesity drugs?

Potential role of statins in COVID-19

The Role of Nutrition in COVID-19 Susceptibility and Severity of Disease: A Systematic Review

studies: more severe forms of COVID-19 disease were observed • In 14 of them, there were higher rates of complications among obese vs nonobese pts NR) 403,535 (NR) • MR: 2

p=0.005) • Advanced respiratory support (ARS): 75% with BMI >25 vs 29% with BMI <25 (OR 6.98, P=0.00001) • Critical illness: 39% with BMI >30 vs 18.1% with BMI <30

studies) • ARS: 1497 pts (630 vs 867) (5 studies) • Critical illness: 4611 pts (1186 vs 3425

I 2 =0.0%) • ↑invasive mechanical ventilation (IMV)

• more severe COVID-19 symptoms (OR 3.03, P=0.003; 4 studies, n=974) • more ARDS (OR 2.89, P=0.025; 2 studies, n=96) • more hospitalizations (OR 1.68, P<0.001; 4 studies, n=6611) • more ICU admissions (OR 1.35, P=0.001; 9 studies, n=5298) • increased need for IMV

Obese patients had similar mortality rates from COVID-19 as non-obese patients

The authors received no financial support for the research, authorship, and/or publication of this article.

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

All authors contributed to the preparation of this manuscript and approved the final version. ASM conceived and designed the project, curated/analyzed the data, wrote the initial draft, and edited the Acknowledgements None